首页> 外文期刊>Surgical and Experimental Pathology >KIT exon 11 and PDGFRA exon 18 gene mutations in gastric GIST: proposal of a short panel for predicting therapeutic response
【24h】

KIT exon 11 and PDGFRA exon 18 gene mutations in gastric GIST: proposal of a short panel for predicting therapeutic response

机译:胃GIST中的KIT外显子11和PDGFRA外显子18基因突变:预测治疗反应的简短小组建议

获取原文
           

摘要

GIST is the most common mesenchymal tumor of gastrointestinal tract and is more frequent in stomach. Its main mutations affect KIT and PDGFRA genes. Full genetic analysis panels are currently used to study mutations in GIST and other tumors. Considering that in gastric GIST KIT gene mutations in exon 11 are sensitive to IM whereas PDGFRΑ gene mutations in exon 18 (D842V) are resistant to the same drug, the aim of this study is to focus on these two molecular targets as a short alternative panel for predicting therapeutic response in gastric GIST which might optimize resources. The genotypes of 38 cases of primary GIST were determined by performing bidirectional DNA sequencing. Exon 11 of KIT gene showed mutations in 65.3% and the exon 18 of PDGFRA gene showed 9% of cases. So it was possible to determine a subgroup of tumors which presented mutations in KIT exon 11 and PDGFRA exon 18. Considering all of the foregoing analyzed globally, the application of short panel has impact on the cost and time of release of results to the physician, allowing a rapid approach to patients eligible for treatment with the target therapy.
机译:GIST是最常见的胃肠道间质瘤,在胃中更为常见。它的主要突变影响KIT和PDGFRA基因。全基因分析小组目前用于研究GIST和其他肿瘤的突变。考虑到第11外显子的胃GIST KIT基因突变对IM敏感,而第18外显子(D842V)的PDGFRA基因突变对同一药物有抗药性,本研究的目的是着眼于这两个分子靶点作为简短的替代选择预测胃GIST的治疗反应可能会优化资源。通过进行双向DNA测序确定38例原发性GIST的基因型。 KIT基因的第11外显子突变率为65.3%,PDGFRA基因的第18外显子突变率为9%。因此,有可能确定在KIT外显子11和PDGFRA外显子18中出现突变的肿瘤亚组。考虑到全局上所有前述分析,短小板的应用影响向医生发布结果的成本和时间,允许对符合目标疗法治疗条件的患者进行快速治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号